share_log

Neonode | 8-K: Current report

SEC ·  Nov 6, 2024 22:22

Summary by Moomoo AI

Neonode Inc. reported Q3 2024 financial results, with revenues from continuing operations at $0.8 million, a slight 0.2% decrease year-over-year. Net loss from continuing operations narrowed to $1.0 million, or $0.07 per share, compared to $1.1 million in Q3 2023. Operating expenses decreased by 2.7% to $2.0 million.License revenues declined 12.6% to $0.7 million due to lower demand from legacy customers, while non-recurring engineering revenues surged to $0.1 million. Cash used by operations improved to $1.3 million from $1.8 million last year. The company ended the quarter with $18.6 million in cash and accounts receivable.Neonode remains optimistic about generating new projects in driver and in-cabin monitoring solutions for the automotive industry. The company's financial position enables execution of its strategy to secure more licensing opportunities for its technologies.
Neonode Inc. reported Q3 2024 financial results, with revenues from continuing operations at $0.8 million, a slight 0.2% decrease year-over-year. Net loss from continuing operations narrowed to $1.0 million, or $0.07 per share, compared to $1.1 million in Q3 2023. Operating expenses decreased by 2.7% to $2.0 million.License revenues declined 12.6% to $0.7 million due to lower demand from legacy customers, while non-recurring engineering revenues surged to $0.1 million. Cash used by operations improved to $1.3 million from $1.8 million last year. The company ended the quarter with $18.6 million in cash and accounts receivable.Neonode remains optimistic about generating new projects in driver and in-cabin monitoring solutions for the automotive industry. The company's financial position enables execution of its strategy to secure more licensing opportunities for its technologies.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more